Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Mi Ran YunDong Hwi KimSeok-Young KimHyeong-Seok JooYou Won LeeHun Mi ChoiChae Won ParkSeong Gu HeoSeok-Gu KangSung Sook LeeAdam J SchoenfeldAlexander E DrilonHyo Sup ShimMin Hee HongJ Jean CuiHye Ryun KimByoung Chul ChoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Repotrectinib is a novel next-generation ROS1-TKI with improved potency and selectivity against treatment-naïve and ROS1G2032R with efficient CNS penetration. Our findings suggest that repotrectinib can be effective both as first-line and after progression to prior ROS1-TKI.